Navigation Links
Avantra Biosciences Launches Multiplex System for Faster, Easier Quantification of Cancer Protein Biomarkers

WOBURN, Mass., Jan. 26, 2011 /PRNewswire/ -- Avantra® Biosciences, a leading innovator in protein diagnostics, announced today their first shipments of the new Q400 Biomarker Workstation and the innovative Angio Qx™ BioChip Immunoassay. The system provides quantitative protein biomarker results for ten analytes in less than an hour, requiring less than five minutes for sample preparation. Multiplex protein assays can be helpful in evaluating the association between elevated protein levels, patient phenotype and drug response.

The Angio Qx Immunoassay is a member of the Avantra QPDx™ biomarker detection product line for use with the Q400 Biomarker Workstation.  This platform consists of a completely self-contained immunoassay BioChip and instrument, for use in the automated measurement of key biomarkers.  

Avantra is currently working with leading experts and institutions on the development of additional biomarker panels directed at specific diseases with an emphasis in the field of oncology for research use only (RUO).  Avantra intends to seek regulatory approval for its assay technologies in the future.

The power and simplicity of Avantra's QPDx platform offers users a rapid, easy-to-use, high quality bench top quantitative multiplex protein assay platform with extremely low CVs and very little setup time.

"The initial shipment of Avantra's QPDx biomarker product line represents the first milestone in Avantra's strategy to develop a suite of oncology focused multiplex biomarker panels.  We see a tremendous opportunity for our QPDx product line and we are excited about the work we are doing with our partners to commercialize additional oncology specific biomarker panels," says Brian McKernan, CEO of Avantra.

About Avantra Biosciences Corporation

Avantra Biosciences is a privately held diagnostics company that has pioneered next-generation technology for protein biomarker analysis.  Initially focused on oncology, Avantra's integrated system enables scientists and clinicians to perform multiplex biomarker analysis for research use only (RUO) from their lab bench or clinical trial site.

Copyright © 2011 Avantra Biosciences Corporation. All rights reserved.

SOURCE Avantra Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration
2. Cell Biosciences Launches New Platform for Multiplex Western Blot Detection
3. Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences
4. Ambit Biosciences Initiates Two Phase I Clinical Trials
5. Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program
6. Cell Biosciences Announces US Patent Issuance
7. Sofie Biosciences Raises $2M to Support Development of Diagnostic Imaging Agents and Devices
8. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
9. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
11. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Post Your Comments:
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
Breaking Medicine News(10 mins):